Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
61 hedge funds and large institutions have $326M invested in Astria Therapeutics in 2022 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 27 increasing their positions, 5 reducing their positions, and 5 closing their positions.
931% more call options, than puts
Call options by funds: $3.31M | Put options by funds: $321K
440% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 5
360% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 5
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
267% more capital invested
Capital invested by funds: $88.8M → $326M (+$237M)
55.02% more ownership
Funds ownership: 75.49% → 130.51% (+55%)
42% more funds holding
Funds holding: 43 → 61 (+18)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$30.7M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$18.7M |
| 3 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$10.2M |
| 4 |
ACM
Altium Capital Management
New York
|
+$9.39M |
| 5 |
PA
Perceptive Advisors
New York
|
+$9.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.48M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$516K |
| 3 |
AG
Artal Group
Luxembourg
|
-$301K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$250K |
| 5 |
AI
ArchPoint Investors
Coral Gables,
Florida
|
-$220K |
ATXS Hedge Fund Activity: Q4 2022 in Review
61 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q4 2022, worth a combined $326M — up 267% from $88.8M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ATXS positions and 5 closed out — a net gain of 18 holders — while 27 added to existing stakes and 5 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $30.7M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $2.48M sold.
- 61 institutional investors held Astria Therapeutics (ATXS) as of Q4 2022, up from 43 in Q3 2022.
- Funds reported $326M of Astria Therapeutics stock for Q4 2022, up 267% quarter-over-quarter.
- 23 funds opened new Astria Therapeutics positions in Q4 2022 and 5 closed out, a net change of +18 holders.
- The largest Astria Therapeutics buyer in Q4 2022 was Fidelity Investments, an estimated $30.7M added.
- The largest Astria Therapeutics seller in Q4 2022 was Alyeska Investment Group, an estimated $2.48M sold.
Based on aggregated 13F filings for Q4 2022.